1-3 of 3
Norbert Avril, MD
Close
Sort by
Journal Articles

Correlation between Tumor Uptake on Indium-111 Ibritumomab Tiuxetan Imaging and Size on CT to Disease Response on FDG PET/CT Scans Obtained Pre- and Post-Yttrium-90 Ibritumomab Tiuxetan Therapy for Non-Hodgkin Lymphoma.

Jacob M. Alexnder, MD, Judith M. Joyce, MD, Barry M. McCook, MD, Norbert Avril, MD, Stephanie R. Land, PhD, Mirsada Begovic, MD, PhD, Samuel A. Jacobs, MD
Journal: Blood
Blood (2005) 106 (11): 4781.
https://doi.org/10.1182/blood.V106.11.4781.4781
Published: 2005
Journal Articles

Cellular Localization Pattern of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) in a Patient with Low-Grade Non-Hodgkin’s Lymphoma (NHL).

Samuel A. Jacobs, MD, Anthony M. Harrison, MD, Steven H. Swerdlow, MD, Kenneth A. Foon, MD, Norbert Avril, MD, Nick Vidnovic, Kenneth S. McCarty, MD, PHD, Wayne Saville, MD
Journal: Blood
Blood (2004) 104 (11): 4569.
https://doi.org/10.1182/blood.V104.11.4569.4569
Published: 2004
Journal Articles

Evaluation of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Non-Hodgkin’s Lymphoma (NHL) Having Previously Received Autologous Stem Cell Transplant (ASCT).

Samuel A. Jacobs, MD, Barry McCook, MD, Frank Torok, MD, Norbert Avril, MD, Nick Vidnovic, Judy Joyce, MD, Arturo Molina, MD
Journal: Blood
Blood (2004) 104 (11): 5238.
https://doi.org/10.1182/blood.V104.11.5238.5238
Published: 2004